Peptide Purity Testing: HPLC vs Mass Spectrometry

Reverse-phase HPLC (RP-HPLC) separates a peptide sample by passing it through a non-polar stationary phase under a gradient of increasingly organic mobile phase. Different molecules elute at different times based on their hydrophobicity, and the detector (typically UV absorbance at 214–220 nm) records the area under each peak. The main peak is the target peptide; smaller peaks are related impurities.

The output is a chromatogram with peaks expressed as a percentage of total integrated peak area. Main-peak purity is the headline number on every credible peptide COA, and the related-impurities profile is the supporting detail.

HPLC measures separation, not identity. Two molecules that elute at the same retention time are quantified as a single peak, even if they are chemically different. A peptide of the wrong sequence but the right hydrophobicity can show as a single clean main peak on HPLC alone — which is why HPLC on its own is not sufficient identity confirmation.

HPLC is also blind to the molecular weight of the eluted peak. A truncated sequence missing a single amino acid can elute close enough to the target peptide to integrate into the same main peak; only mass spectrometry will catch that.

Electrospray mass spectrometry (ESI-MS) ionises the sample and measures the mass-to-charge ratio of the resulting ions. For a peptide, the output is the molecular weight of the molecule — which can then be compared to the theoretical molecular weight calculated from the sequence.

A match within instrument tolerance (typically a fraction of one Dalton for a peptide in the 1–5 kDa range) confirms that the analysed peak is in fact the compound named on the label. A mismatch means the batch is not what the label says it is — the single most serious COA flag.

Mass spectrometry confirms identity, not purity. A clean MS spectrum at the correct molecular weight does not mean the rest of the sample is also at the correct molecular weight — it means the detected ions, in the part of the spectrum the instrument was looking at, match.

Mass spectrometry is also blind to stereochemistry. Two peptides with the same composition but different chirality at one or more residues will have the same molecular weight; only orthogonal methods (circular dichroism, NMR, chiral HPLC) will distinguish them. For most research-grade peptide work this is not a practical concern, but it is worth knowing.

HPLC tells you how clean the batch is. Mass spectrometry tells you whether the clean fraction is what the label says it is. Together they answer the two questions a research-peptide buyer most needs answered: is this the right molecule, and is it pure enough for the protocol?

A COA that includes only HPLC could be reporting a clean batch of the wrong compound. A COA that includes only mass spectrometry could be confirming the right compound in an impure batch. A verified supplier's release specification requires both — HPLC ≥99.0% main peak AND mass-spectrometry molecular weight matching theoretical within tolerance — for every batch.

The HPLC panel shows the chromatogram (retention time on the x-axis, absorbance on the y-axis), the integration table listing each peak with its retention time and percentage area, and the main-peak purity headline number. Look for: a single dominant peak with retention time matching the published method for the compound, related impurities reported as a percentage of total area, and a main-peak purity at or above the release specification.

Methodologically, a 30-minute gradient on a C18 column with UV detection at 214 nm is the standard reverse-phase setup for peptide analysis. Janoshik Analytical publishes its method parameters and they are consistent across a supplier's batch history.

The mass-spectrometry panel shows the ESI spectrum (mass-to-charge on the x-axis, intensity on the y-axis), the deconvoluted molecular weight, the theoretical molecular weight calculated from the sequence, and the difference between the two. For a peptide in the 1–5 kDa range, an agreement within a fraction of one Dalton is the expected tolerance.

For peptides with modifications (e.g. tesamorelin's trans-3-hexenoyl group, fatty-acid acylated analogues), the panel should explicitly confirm the modification — the molecular weight should match the modified sequence, not the base sequence. A panel that reports only the base-sequence weight on a modified peptide is an incomplete identity confirmation.

For most research-peptide batches, HPLC and ESI-MS are sufficient. For complex modifications, isomeric analogues, or batches destined for a particularly sensitive protocol, a verified supplier adds orthogonal methods on request: tandem MS/MS for sequence confirmation, Karl Fischer titration for water content, circular dichroism for secondary-structure confirmation, or chiral HPLC for stereochemistry.

Add-on analytical work is arranged from the supplier and the extended COA is delivered alongside the standard Janoshik report.

The evaluation of peptide pharmaceutical products hinges critically on the determination of their chiral purity. Synthetic peptides are susceptible to the introduction of undesirable D-isomers, which can originate from amino acid starting materials, form during the synthesis process, or even develop during product shelf life (PMID 36857849). Such impurities necessitate rigorous analytical methods to ensure product quality and safety.

Beyond chiral purity, the overall purity of synthetic peptide therapeutics is paramount, as complex structural modifications can arise from starting materials, manufacturing processes, and storage conditions (PMID 34110145). These impurities can impact drug stability and potentially pose safety risks to patients (PMID 33901758). Therefore, host cell proteins (HCPs), for instance, are considered critical quality attributes, and their levels must be closely monitored throughout drug development and in the final drug substance (PMID 33901758). Similarly, for well-established therapies like Betaseron, a genetically engineered analogue of human beta-interferon, purity is assessed using a panel of analytical methods, including non-reducing and reducing SDS-PAGE and reversed-phase HPLC analysis, to identify minor product-related components (PMID 9890522).

Traditional methods for determining amino acid chiral purity in peptides often require derivatization steps and multiple external standards (PMID 36857849). However, a chiral high-performance liquid chromatography-electrospray ionization tandem mass spectrometry (HPLC-ESI-MS/MS) method has been developed to provide rapid and accurate determination of amino acid chiral purity (PMID 36857849). This method involves hydrolyzing the peptide in deuterated acid to correct for racemization during sample preparation, followed by chiral chromatography interfaced with ESI-MS/MS for quantitation (PMID 36857849). This approach simplifies the process by directly analyzing amino acid samples after hydrolysis, avoiding the complexities of derivatization (PMID 36857849). The feasibility of GMP method validation for all nineteen chiral proteogenic amino acids has been described, and the method has been practically applied to detect D-amino acid substitutions in an octapeptide within the 0.1-1.0% range of interest (PMID 36857849). Results obtained using this method for four model peptides, ranging from 8-14 amino acid residues, were comparable to those from traditional testing methods (PMID 36857849).

An earlier high-performance liquid chromatography-electrospray ionization-mass spectrometric (LC-ESI-MS) method also addressed chiral purity determination, where peptides are hydrolyzed in deuterated acid and then derivatized with Marfey's reagent (PMID 7633594). Hydrolysis in a deuterated solvent is crucial because racemization can alter the original D-/L-amino acid ratio during acid hydrolysis (PMID 7633594). Deuterated acids label racemized amino acids with a deuterium at the alpha-carbon, increasing their molecular mass by one atomic unit, allowing mass spectrometry to distinguish them from non-racemized amino acids (PMID 7633594). This procedure was applied to determine the chiral purity of each amino acid in a purified hexapeptide by-product (Arg-Lys-Lys-Asp-Val-Tyr) found in a kilogram batch of the synthetic pentapeptide, thymopentin (PMID 7633594).

Liquid chromatography-mass spectrometry (LC-MS) is increasingly utilized for characterizing impurities in synthetic peptides (PMID 34110145). This approach offers significant advantages by providing critical information beyond traditional purity assessments, such as the identity and relative abundance of individual host cell proteins (HCPs) (PMID 33901758). For instance, an automated iterative MS (HCP-AIMS) workflow allows for deep and unbiased identification and relative quantification of HCPs, even at low abundance (PMID 33901758). This method simplifies sample preparation, requiring only direct digestion without enrichment, and has been shown to identify and quantify HCPs as low as 10 ppm (PMID 33901758).

LC-MS/MS has been instrumental in identifying and characterizing structurally related peptide impurities, as demonstrated with Cbf-14, a novel antimicrobial peptide (PMID 35840670). Using a quadrupole time-of-flight (Q-TOF) mass spectrometer, researchers identified one process-related impurity and thirty-two degradation products, including hydrolysates, isomers, acetylated isomers, aldimine derivatives, and oxidized impurities (PMID 35840670). Similarly, ultrahigh performance liquid chromatography quadrupole-time-of-flight mass spectrometry (UHPLC-QTOF-MS) has been employed to investigate the impurity profile of Norvancomycin hydrochloride, a glycopeptide antibiotic, identifying thirteen impurities and two degradation products (PMID 42571917). These studies underscore the capability of LC-MS techniques to elucidate the chemical structures and formation mechanisms of various peptide impurities (PMID 35840670, PMID 42571917).

A common challenge in peptide analysis is the incompatibility of many liquid chromatography separation conditions with mass spectrometry (MS) detection due to the use of buffers, salts, or additives (PMID 28113090). To overcome this, two-dimensional liquid chromatography (2D-LC) systems have been developed as online desalting tools (PMID 28113090). These systems allow fractions from an MS-incompatible first dimension separation to be sent to a second dimension, where fast desalting with an MS-compatible mobile phase occurs before MS analysis (PMID 28113090). This approach facilitates direct collection of MS information for chromatographic peaks without the need for time-consuming method translation or off-line fraction collection (PMID 28113090).

Further extending this concept, a universal LC-MALDI-MS offline approach has been developed to accelerate biotherapeutic discovery (PMID 40669996). Techniques like size exclusion chromatography (SEC) and hydrophobic interaction chromatography (HIC), often incompatible with electrospray ionization (ESI-MS), can be seamlessly integrated (PMID 40669996). Matrix-assisted laser desorption ionization (MALDI) offers an attractive alternative to ESI due to its rapid analysis and resistance to buffer interferences (PMID 40669996). By combining an LC-fraction collector with MALDI-TOF-MS, this automated workflow enables rapid peak identification for various chromatographic techniques and analytes, including proteins and peptides, within hours (PMID 40669996). This approach eliminates the need for additional method development or sample preparation for MS-based measurements (PMID 40669996).

High-performance liquid chromatography (HPLC) plays a crucial role throughout the manufacturing process of peptide therapeutics, from production to final quality control. For instance, in the production of recombinant human insulin from E. coli, multi-stage purification involves both low-pressure and HPLC techniques to ensure purity (PMID 30735706). At each stage of insulin production, qualitative and quantitative analyses are performed to confirm identity and purity, including studies on molecular weight, insulin amount, and protein impurity content (PMID 30735706). Similarly, Betaseron, a synthetic polypeptide, undergoes purification steps including size exclusion chromatography, and its purity is assessed using a panel of analytical methods, including reversed phase HPLC analysis, to identify minor product-related components (PMID 9890522).

HPLC is also vital for maintaining the quality of radiolabelled peptides, particularly for monitoring radiochemical purity (RCP). For methionine-containing regulatory peptides labeled with (111)In or (177)Lu, HPLC is used to measure and quantify radiolysis and to maintain RCP (PMID 23339763). However, standardization of RCP quantification is lacking, making comparisons between different HPLC systems and laboratories challenging (PMID 23339763). A proposed set of standardized requirements for quantifying RCP by HPLC for radiolabelled DTPA- or DOTA-peptides aims to address this issue (PMID 23339763).

Establishing well-characterized reference standards is fundamental for evaluating the quality of peptide therapeutics, as many analytical tests rely on them to determine identity, purity, and strength (PMID 36949371). The process of producing such standards involves vialing, lyophilization, analytical testing, and stability studies (PMID 36949371). Methods like NMR, mass spectrometry, and chromatography techniques, including HPLC, are utilized for identity testing and assessing peptide content and impurities (PMID 36949371). A two-step value assignment process is often employed, using a mass balance approach for bulk peptide material, which then serves as a standard for the final vialed material (PMID 36949371). Testing also confirms peptide identity and consistency of the vialed material, with considerations for variability, outlier identification, and stability studies (PMID 36949371). These practices provide a benchmark for establishing peptide reference standards in the pharmaceutical industry (PMID 36949371).

The integration of LC-MS peptide mapping into a multi-attribute method (MAM) workflow is poised to replace multiple conventional HPLC and capillary electrophoresis-based purity/impurity assays for release and stability testing of protein biopharmaceuticals (PMID 41084101). A crucial component of this is new peak detection (NPD) functionality, which reliably identifies new, absent, and changed peptide species that could impair drug quality (PMID 41084101). A robust NPD workflow, validated according to ICH Q2 guidelines, has been developed to detect relevant peptide species below 1% relative abundance without false positives (PMID 41084101). This signifies a substantial advancement in using MAM as a quality control tool (PMID 41084101).

Despite advances, challenges persist in peptide analysis, particularly with complex structures or unusual properties. For example, the identification of 'Melanotan II,' a small peptide weighing 1024 Da, proved challenging for forensic scientists due to its molecular weight exceeding the typical detection range (up to 1000 Da) of some mass spectrometers and its multi-charged nature (PMID 39302005). Furthermore, its UV spectrum was not initially available in literature, complicating identification by HPLC-DAD (PMID 39302005). These difficulties in detection may contribute to its popularity on the illicit market (PMID 39302005).

The characterization of structurally modified peptides, such as biphalin, an opioid octapeptide with a palindromic sequence, also presents challenges where standard techniques may be inadequate (PMID 11168898). While techniques like elemental analysis, amino acid analysis, HPLC, and capillary electrophoresis (CE) are used, electrospray ionization (ESI) mass spectrometry, including ESI-MS and ESI-MS/MS, is critical for confirming the full peptide sequence, as amino acid sequence analysis alone may only verify monomer sequences (PMID 11168898). Even for degradation impurities, such as a new cetrorelix methylene dimer impurity, LC-MS/MS methods are developed for separation, identification, and characterization, highlighting the importance of understanding the impact of environmental factors like formaldehyde on peptide quality (PMID 33611089).

Forced degradation studies, which involve exposing active pharmaceutical ingredients (APIs) to harsh conditions, are crucial for understanding degradation pathways and selecting appropriate packaging and storage conditions (PMID 34056545). For instance, the TGR5 receptor agonist ZY12201, when subjected to oxidative degradation, showed an oxidative impurity detectable by HPLC, which was subsequently characterized by LC-MS to elucidate its structure and degradation pathway (PMID 34056545). Similarly, ubrogepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist, was found to be labile to acidic hydrolysis, basic hydrolysis, and oxidative degradation during forced degradation studies (PMID 38522383).

LC-HRMS and NMR techniques are employed for the identification and characterization of degradation impurities (PMID 38522383). For ubrogepant, eight degradation impurities were separated by reversed-phase HPLC, and their structures were characterized using exact masses from HRMS/MS, with further NMR studies on major impurities (PMID 38522383). A plausible mechanism was proposed for the degradation impurities (PMID 38522383). In silico tools, such as Zeneth for degradation profile prediction and DEREK Nexus, SARAH Nexus, and ProTox-II for toxicity and mutagenicity assessment, complement experimental findings in understanding the stability and safety of peptide therapeutics (PMID 38522383).

• Enantiomeric purity analysis of synthetic peptide therapeutics by direct chiral high-performance liquid chromatography-electrospray ionization tandem mass spectrometry. — Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (2023). PMID 36857849
• Expression and purification of recombinant human insulin from E. coli 20 strain. — Protein expression and purification (2019). PMID 30735706
• Betaseron. — Developments in biological standardization (1998). PMID 9890522
• Peptide chiral purity determination: hydrolysis in deuterated acid, derivatization with Marfey's reagent and analysis using high-performance liquid chromatography-electrospray ionization-mass spectrometry. — Journal of chromatography. A (1995). PMID 7633594
• Barbie drug identification: Not a child's play. — Journal of forensic sciences (2024). PMID 39302005
• Characterization and analysis of biphalin: an opioid peptide with a palindromic sequence. — The journal of peptide research : official journal of the American Peptide Society (2001). PMID 11168898
• Effectiveness of quenchers to reduce radiolysis of (111)In- or (177)Lu-labelled methionine-containing regulatory peptides. Maintaining radiochemical purity as measured by HPLC. — Current topics in medicinal chemistry (2012). PMID 23339763
• Reference Standards to Support Quality of Synthetic Peptide Therapeutics. — Pharmaceutical research (2023). PMID 36949371
• Toward unbiased identification and comparative quantification of host cell protein impurities by automated iterative LC-MS/MS (HCP-AIMS) for therapeutic protein development. — Journal of pharmaceutical and biomedical analysis (2021). PMID 33901758
• Development, qualification, and application of a highly efficient and robust new peak detection workflow for the LC-MS peptide mapping multi-attribute method. — mAbs (2025). PMID 41084101
• 2D-LC as an on-line desalting tool allowing peptide identification directly from MS unfriendly HPLC methods. — Journal of pharmaceutical and biomedical analysis (2017). PMID 28113090
• Characterization of structurally related peptide impurities using HPLC-QTOF-MS/MS: application to Cbf-14, a novel antimicrobial peptide. — Analytical and bioanalytical chemistry (2022). PMID 35840670
• Identification of Impurities in Norvancomycin Hydrochloride Drug Substance Using UHPLC-QTOF-MS. — Rapid communications in mass spectrometry : RCM (2026). PMID 42571917
• Characterization of Synthetic Peptide Therapeutics Using Liquid Chromatography-Mass Spectrometry: Challenges, Solutions, Pitfalls, and Future Perspectives. — Journal of the American Society for Mass Spectrometry (2021). PMID 34110145
• Accelerating biotherapeutics discovery: Blueprint for a universal LC-MALDI-MS offline approach. — Analytica chimica acta (2025). PMID 40669996
• Identification of degradation impurity of TGR5 receptor agonist-ZY12201 by LC-MS technique during force degradation study. — SN applied sciences (2021). PMID 34056545
• Identification and structural elucidation of a new cetrorelix methylene dimer impurity in cetrorelix acetate by using LC-MS/MS. — Journal of pharmaceutical and biomedical analysis (2021). PMID 33611089
• LC-HRMS and NMR studies for the characterization of degradation impurities of ubrogepant along with the in silico approaches for the prediction of degradation and toxicity. — Journal of pharmaceutical and biomedical analysis (2024). PMID 38522383